These include assessment of AZD4547 at the RD of 80 mg bid in FGFR2-amplified GC and FGFR1-amplified BC (NCT01457846; NCT01795768) [35, 41], BGJ398 in patients with advanced FGFR-altered colangiocarcinoma [38], and JNJ-42756493 in patients with metastatic or unresectable UC with FGFR gene alterations [42]. This evidence concerns the gene FGFR1 and breast cancer.